Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models

Summary

Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models is a doctoral thesis^[1].

Key Facts

• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models authored Rachelle S Singleton^[2].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's instance of is recorded as doctoral thesis^[3].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's publisher is recorded as ResearchSpace@Auckland^[4].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's copyright license is recorded as Creative Commons Attribution-NonCommercial-ShareAlike 3.0 New Zealand^[5].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's country of origin is recorded as New Zealand^[6].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's publication date is recorded as +2008-00-00T00:00:00Z^[7].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's main subject is recorded as medical sciences^[8].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's main subject is recorded as biomarker^[9].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's main subject is recorded as hypoxia^[10].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's work available at URL is recorded as https://researchspace.auckland.ac.nz/handle/2292/3286^[11].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's Handle ID is recorded as 2292/3286^[12].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's title is recorded as Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models^[13].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's copyright holder is recorded as Rachelle S Singleton^[14].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's thesis submitted to is recorded as University of Auckland^[15].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's on focus list of Wikimedia project is recorded as NZThesisProject^[16].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's copyright status is recorded as copyrighted^[17].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's online access status is recorded as open access^[18].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's thesis committee member is recorded as William Robert Wilson^[19].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's thesis committee member is recorded as Bronwyn G. Siim^[20].
• Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's thesis committee member is recorded as Adam Patterson^[21].

Body

Designation and Status

Relationships between reductive metabolism, DNA damage and antitumour activity of the hypoxia-activated prodrug PR-104 in preclinical models's instance of is recorded as doctoral thesis^[3].